Medications for Hyperparathyroidism Secondary

22 results

  • Calcitriol (calcitriol 0.25 mcg)

    (Calcitriol 0.25 mcg)
    ATLANTIC BIOLOGICALS CORP.
    Usage: Calcitriol is indicated for managing secondary hyperparathyroidism in predialysis patients with chronic renal failure, hypocalcemia in dialysis patients, and hypocalcemia due to postsurgical or idiopathic hypoparathyroidism. It enhances calcium absorption and may reduce parathyroid hormone levels and bone disease manifestations.

  • Calcitriol (calcitriol capsules 0.25 mcg)

    (Calcitriol Capsules 0.25 mcg)
    Aphena Pharma Solutions - Tennessee, LLC
    Usage: Calcitriol capsules are indicated for managing secondary hyperparathyroidism in predialysis patients with chronic renal failure, hypocalcemia in dialysis patients, and hypocalcemia in individuals with hypoparathyroidism, including postsurgical and idiopathic cases. It promotes calcium absorption and reduces associated metabolic bone disease effects.

  • Calcitriol (calcitriol)

    (Calcitriol)
    Sun Pharmaceutical Industries, Inc.
    Usage: Calcitriol is indicated for managing secondary hyperparathyroidism in predialysis patients with chronic renal failure, hypocalcemia in dialysis patients, and hypocalcemia related to postsurgical, idiopathic, or pseudohypoparathyroidism. It helps enhance calcium absorption and alleviate metabolic bone disease.

  • Calcitriol (calcitriol)

    (Calcitriol)
    Aphena Pharma Solutions - Tennessee, LLC
    Usage: Calcitriol capsules are indicated for managing secondary hyperparathyroidism in predialysis patients with chronic renal failure, addressing hypocalcemia and metabolic bone disease in dialysis patients, and treating hypocalcemia in individuals with postsurgical, idiopathic, or pseudohypoparathyroidism.

  • Calcitriol (calcitriol)

    (Calcitriol)
    ATLANTIC BIOLOGICALS CORP.
    Usage: Calcitriol is indicated for managing secondary hyperparathyroidism in predialysis patients with chronic renal failure, hypocalcemia in dialysis patients, and hypocalcemia in individuals with postsurgical, idiopathic, or pseudohypoparathyroidism. It helps improve calcium absorption and may reduce parathyroid hormone levels and related bone complications.

  • Cinacalcet (cinacalcet)

    (Cinacalcet)
    American Health Packaging
    Usage: Cinacalcet is indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in parathyroid carcinoma, and severe hypercalcemia in primary hyperparathyroidism patients who cannot undergo surgery. It is not indicated for non-dialysis patients due to hypocalcemia risk.

  • Cinacalcet (cinacalcet)

    (Cinacalcet)
    AvPAK
    Usage: Cinacalcet tablets are indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in adults with primary hyperparathyroidism who cannot undergo parathyroidectomy. It is not recommended for patients with CKD not on dialysis due to hypocalcemia risk.

  • Cinacalcet (cinacalcet)

    (Cinacalcet)
    Bryant Ranch Prepack
    Usage: Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in parathyroid carcinoma, and severe hypercalcemia in primary hyperparathyroidism patients who cannot undergo surgery. It is not recommended for those with chronic kidney disease not on dialysis due to hypocalcemia risk.

  • Cinacalcet (cinacalcet)

    (Cinacalcet)
    Camber Pharmaceuticals, Inc.
    Usage: Cinacalcet tablets are indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in parathyroid carcinoma, and severe hypercalcemia in primary hyperparathyroidism when surgery is not an option. Not indicated for non-dialysis CKD patients due to hypocalcemia risk.

  • Cinacalcet (cinacalcet)

    (Cinacalcet)
    Aurobindo Pharma Limited
    Usage: Cinacalcet tablets are indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in parathyroid carcinoma patients, and hypercalcemia in primary hyperparathyroidism when parathyroidectomy is not an option. Not for use in CKD patients not on dialysis due to hypocalcemia risk.